Medpace (MEDP) to Post Earnings on Wednesday

Medpace (NASDAQ:MEDP) is projected to release its Q2 2026 results after the market closes on Wednesday, July 22nd. Analysts expect the company to post earnings of $3.98 per share and revenue of $690.6580 million for the quarter. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Parties are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 23, 2026 at 9:00 AM ET.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same period in the previous year, the company earned $3.67 earnings per share. The firm’s revenue for the quarter was up 26.5% on a year-over-year basis. On average, analysts expect Medpace to post $17 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Medpace Trading Up 1.1%

NASDAQ MEDP opened at $536.17 on Wednesday. The firm has a market capitalization of $15.31 billion, a P/E ratio of 33.70, a price-to-earnings-growth ratio of 2.69 and a beta of 1.15. The firm’s fifty day moving average price is $471.59 and its two-hundred day moving average price is $494.96. Medpace has a 1 year low of $306.70 and a 1 year high of $628.92.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Robert W. Baird reiterated a “neutral” rating and issued a $547.00 target price (up from $477.00) on shares of Medpace in a research note on Wednesday, July 8th. Barclays lowered their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. BMO Capital Markets dropped their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Mizuho raised their price objective on Medpace from $495.00 to $586.00 and gave the company an “outperform” rating in a research report on Monday. Finally, Royal Bank Of Canada reduced their target price on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Two analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $469.50.

Insiders Place Their Bets

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 20.50% of the stock is owned by insiders.

Institutional Trading of Medpace

Institutional investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. increased its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Quarry LP acquired a new stake in Medpace during the third quarter worth approximately $35,000. Greenline Wealth Management LLC bought a new position in Medpace during the 4th quarter worth $55,000. Group One Trading LLC increased its stake in Medpace by 120.0% during the 4th quarter. Group One Trading LLC now owns 100 shares of the company’s stock worth $56,000 after acquiring an additional 600 shares during the period. Finally, Johnson Financial Group Inc. raised its holdings in Medpace by 115.7% in the 3rd quarter. Johnson Financial Group Inc. now owns 110 shares of the company’s stock valued at $57,000 after acquiring an additional 59 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.